ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Pharmaceuticals | Rituxan | Treanda